Metropolol tartrate
Due to its effects on the respiratory system, Metropolol tartrate is contraindicated in patients with this chronic inflammatory airway disease.
Asthma
Lovastatin belongs to this specific category of antihyperlipidemics.
Hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins)
Fenofibrate belongs to this drug category, which targets hypertriglyceridemia.
Fibric acid derivitives (fibrates)
For all antihyperlipidemics, nurses should monitor cholesterol and triglycerides levels as well as these organ function tests.
Liver function tests
Patients taking Metropolol tartrate should be warned that the drug can cause this type of impairment in sexual health.
Sexual dysfunction
Statins like Lovastatin inhibit the enzyme that catalyzes the rate limiting step in this biological process.
Cholesterol biosynthesis
Fenofibrate acts as an antagonist for this specific receptor to increase lipoprotein lipase.
Peroxisome proliferator-activated receptor-alpha (PPAR-alpha)
Across diuretic and anti hypersensitive classes, this common nursing consideration involves measuring both pressure and electrolyte levels, especially this ion.
Potassium
A critical nursing consideration for Metropolol tartrate is that it should never be stopped in this manner.
Never abruptly discontinue
Lovastatin is contraindicated in patients with breastfeeding, pregnancy, or this acute organ condition.
Active liver disease
By increasing fatty acid oxidation, Fenofibrate increases the breakdown of this specific lipoprotein.
Very low-density lipoprotein (VLDL).
Nursing considerations for Lovastatin include advising the patient to avoid taking the medication with this natural supplement.
This severe adverse effect of Lovastatin involves the breakdown of damaged skeletal muscle.
Rhabdomyolysis
Fenofibrate is contraindicated in patients with primary biliary cirrhosis or this condition affecting the bile storage organ.
Gallbladder disease
This potentially fatal skin reaction, characterized by sheet-like loss of skin, is delayed hypersensitivity risk for Fenofibrate.
Stevens-Johnson syndrome
Patients should be instructed to take immediate-release Lovastatin tablets at this specific time of day.
With the evening meal
This painful musculoskeletal adverse effect in the lower extremities is associated with Fenofibrate use.
Leg cramps